Primary ciliary dyskinesia, a rare disease causing bronchiectasis, lacks a sound evidence base for treatment. @beatpcd proposes 1) forming a PCD European clinical trial network to address this situation and 2) conducting n-of-1 trials to access medication. https://bit.ly/3j5blfM.

3rd Dept of Paediatrics University General Hospital Attikon National and Kapodistrian University of Athens Athens Greece

AP HP Hôpital Kremlin Bicetre Service d'ORL et de Chirurgie Cervico Faciale and Faculté de Médecine Université Paris Saclay 94070 Le Kremlin Bicêtre INSERM U955 and CNRS ERL 7240 Créteil France

Centro Materno Pediátrico Centro Hospitalar Universitário de S João Porto Portugal

Children's Hospital for Lung Diseases and TB Medical Centre Dr Dragisa Misovic Belgrade Serbia

Danish PCD Centre Pediatric Pulmonary Service Dept of Pediatrics and Adolescent Medicine Rigshospitalet Copenhagen Denmark

Departamento de Ginecologia Obstetrícia e Pediatria Faculdade de Medicina Universidade do Porto Porto Portugal

Dept of General Pediatrics University Hospital Westfalian Wilhelms University Muenster Germany

Dept of Molecular and Clinical Genetics Institute of Human Genetics Polish Academy of Sciences Poznan Poland

Dept of Paediatrics University Hospital Gasthuisberg Leuven Belgium

Dept of Pediatric Pulmonology Marmara University School of Medicine Istanbul Turkey

Dept of Pediatric Pulmonology VU University Medical Center Amsterdam The Netherlands

Dept of Pediatrics and Marsico Lung Institute University of North Carolina at Chapel Hill Chapel Hill NC USA

Depts of Paediatrics and Paediatric Respiratory Medicine Imperial College and Royal Brompton Hospital London UK

Division of Paediatric Pulmonology and Allergology Dept of Paediatrics and Adolescent Medicine Medical University of Graz Graz Austria

European Academy of Paediatrics Brussels Belgium

Faculty of Pharmacy Novi Sad Business Academy Novi Sad Serbia

Institute of Social and Preventive Medicine and Paediatric Respiratory Medicine Children's University Hospital of Bern University of Bern Bern Switzerland

Medical School University of Cyprus Nicosia Cyprus

Paediatric Dept 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Paediatric Dept for Lung and Allergic diseases Oslo University Hospital Oslo Norway

Patient Association Kartagener Syndrom und Primäre Ciliäre Dyskinesie e 5 Steffisburg Switzerland

Pediatric Pulmonology Dept of Translational Medical Sciences Federico 2 University Azienda Ospedaliera Universitaria Federico 2 Naples Italy

Pediatric Pulmonology Section Hospital Universitari Vall d'Hebron Barcelona Spain

Primary Ciliary Dyskinesia Centre University Hospital Southampton NHS Foundation Trust and Clinical and Experimental Medicine University of Southampton Southampton UK

Queen Silvias Children's Hospital Sahlgrenska University Hospital Gothenburg Sweden

Schneider Children's Medical Center of Israel Petach Tikva and Sackler School of Medicine Tel Aviv University Tel Aviv Israel

Universitat Autònoma de Barcelona CIBERER Barcelona Spain

Vilnius University Medical Faculty Institute of Clinical Medicine Clinic of Children's Diseases Vilnius Lithuania

See more in PubMed

Ferreira CR. The burden of rare diseases. Am J Med Genet 2019; 179A: 885–892. doi:10.1002/ajmg.a.61124 PubMed DOI

Richter T, Nestler-Parr S, Babela R, et al. . Rare disease terminology and definitions-a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health 2015; 18: 906–914. doi:10.1016/j.jval.2015.05.008 PubMed DOI

Tadrous M, Khuu W, Paterson JM, et al. . Off-label use of inhaled tobramycin in Ontario, Canada. Thorax 2016; 71: 862–864. doi:10.1136/thoraxjnl-2015-208145 PubMed DOI

Goutaki M, Meier AB, Halbeisen FS, et al. . Clinical manifestations in primary ciliary dyskinesia: systematic review and meta-analysis. Eur Respir J 2016; 48: 1081–1095. doi:10.1183/13993003.00736-2016 PubMed DOI

Kuehni CE, Frischer T, Strippoli M-PF, et al. . Factors influencing the age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J 2010; 36: 1248–1258. doi:10.1183/09031936.00001010 PubMed DOI

Goutaki M, Maurer E, Halbeisen FS, et al. . The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results. Eur Respir J 2017; 49: 1601181. doi:10.1183/13993003.01181-2016 PubMed DOI PMC

Behan L, Galvin AD, Rubbo B, et al. . Diagnosing primary ciliary dyskinesia: an international patient perspective. Eur Respir J 2016; 48: 1096–1107. doi:10.1183/13993003.02018-2015 PubMed DOI PMC

Behan L, Dimitrov BD, Kuehni CE, et al. . PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. Eur Respir J 2016; 47: 1103–1112. doi:10.1183/13993003.01551-2015 PubMed DOI PMC

Lucas JS, Barbato A, Collins SA, et al. . European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 2017; 49: 1601090. doi:10.1183/13993003.01090-2016 PubMed DOI PMC

Lucas JS, Davis SD, Omran H, et al. . Primary ciliary dyskinesia in the genomics age. Lancet Respir Med 2020; 8: 202–216. doi:10.1016/S2213-2600(19)30374-1 PubMed DOI

Lucas JS, Alanin MC, Collins S, et al. . Clinical care of children with primary ciliary dyskinesia. Expert Rev Respir Med 2017; 11: 779–790. doi:10.1080/17476348.2017.1360770 PubMed DOI

Paff T, Daniels JM, Weersink EJ, et al. . A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia. Eur Respir J 2017; 49: 1601770. doi:10.1183/13993003.01770-2016 PubMed DOI

Kobbermagel HE, Buchvald FF, Haarman EG, et al. . Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicenter, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2020; 8: 493–505. doi:10.1016/S2213-2600(20)30058-8 PubMed DOI

Higgins KL, Noda C, Stultz JS. Extended interval tobramycin pharmacokinetics in a pediatric patient with primary ciliary dyskinesia presenting with an acute respiratory exacerbation. J Pediatr Pharmacol Ther 2018; 23: 159–163. PubMed PMC

O'Donnell AE, Barker AF, Ilowite JS, et al. . Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329–1334. doi:10.1378/chest.113.5.1329 PubMed DOI

Crowley S, Holgersen MG, Nielsen KG. Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers. Chron Respir Dis 2019; 16: 1479972318787919. doi:10.1177/1479972318787919 PubMed DOI PMC

Czech M, Baran-Kooiker A, Atikeler K, et al. . A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. Front Public Health 2019; 7: 416. doi:10.3389/fpubh.2019.00416 PubMed DOI PMC

Marthin JK, Petersen N, Skovgaard LT, et al. . Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010; 181: 1262–1268. doi:10.1164/rccm.200811-1731OC PubMed DOI

Halbeisen FS, Goutaki M, Spycher BD, et al. . Lung function in patients with primary ciliary dyskinesia: an iPCD Cohort study. Eur Respir J 2018; 52: 1801040. doi:10.1183/13993003.01040-2018 PubMed DOI

Eden E, Choate R, Barker A, et al. . the clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia–Results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis 2019; 6: 145–153. PubMed PMC

Bush A, Payne D, Pike S, et al. . Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis. Chest 2006; 129: 118–123. doi:10.1378/chest.129.1.118 PubMed DOI

Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2018; 9: CD001127. PubMed PMC

Desai M, Weller PH, Spencer DA. Clinical benefit from nebulized recombinant DNase in Kartagener's syndrome. Pediatr Pulmonol 1995; 20: 307–308. doi:10.1002/ppul.1950200509 PubMed DOI

ten Berge M, Brinkhorst G, Kroon AA, et al. . DNase treatment in primary ciliary dyskinesia: assessment by nocturnal pulse oximetry. Pediatr Pulmonol 1999; 27: 59–61. doi:10.1002/(SICI)1099-0496(199901)27:1<59::AID-PPUL11>3.0.CO;2-D PubMed DOI

El-Abiad NM, Clifton S, Nasr SZ. Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia. Respir Med 2007; 101: 2224–2226. doi:10.1016/j.rmed.2007.05.014 PubMed DOI

Wilkinson M, Sugumar K, Milan SJ, et al. . Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2014; 5: CD001289. PubMed PMC

Shapiro AJ, Zariwala MA, Ferkol T, et al. . Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol 2016; 51: 115–132. doi:10.1002/ppul.23304 PubMed DOI PMC

JHL Biotech, Inc. A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme in Healthy Subjects. ClinicalTrials.gov Identifier: NCT03586076. Date last updated: 7 January 2020 https://clinicaltrials.gov/ct2/show/NCT03586076

Poeta M, Borelli M, Santamaria F. Azithromycin for primary ciliary dyskinesia: a milestone. Lancet Respir Med 2020; 8: 429–430. doi:10.1016/S2213-2600(20)30100-4 PubMed DOI

Maglione M, Bush A, Nielsen KG, et al. . Multicenter analysis of body mass index, lung function, and sputum microbiology in primary ciliary dyskinesia. Pediatr Pulmonol 2014; 49: 1243–1250. doi:10.1002/ppul.22984 PubMed DOI

Chang H, Adjemian J, Dell SDM, et al. . Similarities between CF and PCD: Airway pathogens and lung function. Prevalence of airway microbial flora in primary ciliary dyskinesia. Am J Respir Crit Care Med 2015; 191: A1798.

Frija-Masson J, Bassinet L, Honoré I, et al. . Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia. Thorax 2017; 72: 154–160. doi:10.1136/thoraxjnl-2015-207891 PubMed DOI

World Health Organization (WHO regional office for Europe). Medicines reimbursement policies in Europe, 2018. https://www.euro.who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf Accessed 21 May 2020.

Kuehni CE, Goutaki M, Kobbernagel HE. Hypertonic saline in patients with primary ciliary dyskinesia: on the road to evidence-based treatment for a rare lung disease. Eur Respir J 2017; 49: 1602514. doi:10.1183/13993003.02514-2016 PubMed DOI